Results from masitinib study AB12003 in prostate cancer have been presented at the 2021 American Urological Association
13/09/2021 – AB Science today announced that results from masitinib study AB12003 in metastatic castrate refractory prostate cancer, have been presented as a podium presentation at the 2021 American Urological Association